- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.10. | OS Therapies Inc - 8-K, Current Report | 3 | SEC Filings | ||
| 19.10. | OS Therapies: OS Therapies Announces Initial Closing of Warrant Exercise Inducement and Exchange Offer for Initial Gross Proceeds of Approximately $7.2 Million | 649 | Newsfile | Proceeds from the initial closing, together with accrued refundable U.K. R&D tax credits, expected to provide operating runway through major upcoming milestonesCompany expects to complete early market... ► Artikel lesen | |
| 07.10. | OS Therapies: OS Animal Health Receives USDA Feedback on Regulatory Pathway for OST-HER2 in Canine Osteosarcoma | 499 | Newsfile | Received notice for upcoming USDA meetingCompany is reviewing strategic alternatives to monetize OS Animal Health ("OSAH")Grasonville, Maryland--(Newsfile Corp. - October 7, 2026) - OS Therapies, Inc.... ► Artikel lesen | |
| 06.10. | OS Therapies Reports Significant Three-Year Survival Data for Bone Cancer Treatment | 1 | Benzinga.com | ||
| 06.10. | OS Therapies: OS Therapies Achieves Statistically Significant Final Three-Year Overall Survival Benefit for Herlystic-Treated Patients in Phase 2b Pulmonary Metastatic Osteosarcoma Trial | 608 | Newsfile | Leading Clinical Stage Oncology Company Releases Significant Findings from OST-HER2-Treated Patients72.7 percent three-year overall survival vs. 45.8 percent comparable combined historical control (p... ► Artikel lesen | |
| 05.10. | OS Therapies Inc - 8-K, Current Report | 1 | SEC Filings | ||
| OS THERAPIES Aktie jetzt für 0€ handeln | |||||
| 01.10. | OS Therapies appoints Kerry Clem as CCO, Frank Knuettel II as CFO | 2 | Seeking Alpha | ||
| 01.10. | OS Therapies: OS Therapies Appoints Kerry Clem as Chief Commercial Officer and Frank Knuettel II as Chief Financial Officer | 514 | Newsfile | Experienced biotech leaders to focus on preparations for U.S., U.K., and European commercial launch of the Company's lead product candidate Herlystic(OST-HER2; daznelimgene lisbac)Grasonville, Maryland--(Newsfile... ► Artikel lesen | |
| 24.09. | OS Therapies: OS Therapies Announces Brand Name 'Herlystic' Approved by World Health Organization for OST-HER2 (daznelimgene lisbac) | 504 | Newsfile | New York, New York and Rockville, Maryland--(Newsfile Corp. - September 24, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or the "Company"), the world leader in gene-edited, Listeria-based... ► Artikel lesen | |
| 21.09. | OS Therapies: OS Therapies Completes FDA Type C Statistical Methods Meeting and Provides Update on Global Regulatory Coordination for OST-HER2 Under Project Orbis | 739 | Newsfile | Recent U.K. MHRA Scientific Advice Meeting (SAM) that resulted in full alignment to initiate confirmatory Phase 3 trial in U.K. with existing Phase 2 drug product paved the way Conditional Marketing... ► Artikel lesen | |
| 17.09. | OS Therapies: OS Therapies Achieves Incremental Alignment With FDA and Accepts Project Orbis Invitation From MHRA on OST-HER2 Metastatic Osteosarcoma Program | 728 | Newsfile | FDA aligns with MHRA and EMA on adaptive design for Phase 3 trialAfter successful Scientific Advice Meeting, Company accepts MHRA request to become he Company's' sponsor into Project Orbis to harmonize... ► Artikel lesen | |
| 15.09. | OS Therapies: OS Therapies Announces Full Alignment with UK MHRA and EU EMA for Conditional Marketing Authorisation Application Filing | 517 | Newsfile | Overall Survival (OS) historical-control data gains HMRA and EMA support for pending CMAA submissionsFull alignment achieved on confirmatory Phase 3 trial designComplete CMAA submission expected in... ► Artikel lesen | |
| 09.09. | OS Therapies Inc - 8-K, Current Report | 1 | SEC Filings | ||
| 08.09. | OS Therapies Reports Strong Survival Data for Bone Cancer Treatment | 1 | Benzinga.com | ||
| 08.09. | OS Therapies: OS Therapies Achieves Statistically Significant Benefit for OST-HER2-Treated Patients in Interim 3-Year Overall Survival Analysis of Phase 2b Pulmonary Metastatic Osteosarcoma Trial | 534 | Newsfile | 71.2% 3-year overall survival for OST-HER2-treated patients vs. 45.8% comparable combined historical control (p = 0.002)The two remaining patients who have not yet reached the 3-year timepoint from... ► Artikel lesen | |
| 02.09. | OS Therapies: OS Therapies Provides OST-HER2 Metastatic Osteosarcoma Program Update and Announces Upcoming Conference Attendance | 840 | Newsfile | Management will participate at Jefferies Global Healthcare Conference, H.C. Wainwright Global Investment Conference, ROTH Healthcare Opportunities Conference Management and business development advisors... ► Artikel lesen | |
| 21.08. | OS Therapies Inc - 8-K, Current Report | 1 | SEC Filings | ||
| 19.08. | OS Therapies Secures Up To $10 Million Debt Financing Against U.K. Tax Refunds And R&D Credits | 1 | pulse2.com | ||
| 17.08. | OS Therapies GAAP EPS of -$0.20 misses by $0.03 | 1 | Seeking Alpha | ||
| 17.08. | OS Therapies: OS Therapies Reports Second Quarter 2026 Financials and Provides Business and Regulatory Updates | 1.062 | Newsfile | Up to $10 million debt financing supported by U.K. subsidiary VAT refunds and reimbursable R&D tax credits, including $5 million funded at the August 10, 2026 first closingFDA Type C Statistical... ► Artikel lesen |
1 2 3 4 Weiter >>
64 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,540 | -0,59 % | Valneva bekommt eine 3-: Warum unsere Experten so vorsichtig urteilen - Mein Rat: sofort handeln! | ||
| CRISPR THERAPEUTICS | 48,620 | +0,30 % | Inventiva (IVA) vs. CRSP and MDGL: Can Lanifibranor's Phase 3 Trial Unlock 62% Upside? | ||
| PALATIN TECHNOLOGIES | 5,110 | +3,65 % | Palatin Technologies, Inc.: Palatin Reports Fiscal Year 2026 Financial Results and Provides Business Update | Programs are focused on rare obesity disorders associated with the melanocortin 4 receptor (MC4R) pathway, including hypothalamic obesity, Prader-Willi syndrome... ► Artikel lesen | |
| OCUGEN | 0,684 | +1,48 % | Ocugen mit BRANDMELDUNG: Folgt jetzt der nächste Kursrutsch? - Handeln Sie, bevor es zu spät ist! | ||
| VIVORYON THERAPEUTICS | 0,826 | +0,24 % | Vivoryon Therapeutics N.V. Reports Outcome of 2026 Annual General Meeting | Vivoryon Therapeutics N.V. Reports Outcomeof 2026 Annual General Meeting
Halle (Saale) / Munich, Germany, September 29, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7)... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 17,280 | +0,47 % | H.C. Wainwright bekräftigt Verkaufsempfehlung für Sarepta Therapeutics - Kursziel 5 US-Dollar | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 2,517 | -0,40 % | Here's Why You Should Hold PacBio Stock in Your Portfolio for Now | ||
| REDHILL BIOPHARMA | 0,404 | -3,12 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -4- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS1509643029 CENNTRO... ► Artikel lesen | |
| IMMUNIC | 7,068 | +5,43 % | EQS-News: Immunic AG: Immunic to Host Virtual Progressive Multiple Sclerosis R&D Day on November 5, 2026 | Issuer: Immunic AG
/ Key word(s): Conference
Immunic to Host Virtual Progressive Multiple Sclerosis R&D Day on November 5, 2026
29.10.2026 / 11:30 CET/CEST
The issuer... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 0,880 | -0,24 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series | Live Presentation and Q&A: Tuesday, October 20, 2026 12 PM EDTKing of Prussia, Pennsylvania--(Newsfile Corp. - October 19, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 6,600 | +0,76 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Second Quarter 2026 Financial Results and Business Highlights | Ocular's AXPAXLITM wet AMD NDA submission on track for Q4 2026 following positive Type C Meeting with the U.S. FDA in May 2026 FDA Type C Meeting Minutes Formalize SOL-1 Trial with Confirmatory Evidence... ► Artikel lesen | |
| VERASTEM | 8,676 | +0,14 % | Novocure and Verastem to Test Combined Therapies for Locally Advanced Pancreatic Cancer | ||
| OXFORD NANOPORE TECHNOLOGIES | 2,830 | +1,00 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 19.10.2026 | Folgende Wertpapiere werden in den Handel an der Frankfurter Wertpapierbörse (FWB) aufgenommen.
1. US88025U1097 10X GENOMICS INC
2. NL0000852564 AALBERTS NV
3. SE0016589188 ELECTROLUX AB
4. SE0000115446... ► Artikel lesen | |
| ROCKET PHARMACEUTICALS | 2,360 | +3,51 % | Rocket Pharma upgraded at Goldman Sachs on Danon disease therapy | ||
| VOYAGER THERAPEUTICS | 1,633 | +3,22 % | Voyager Therapeutics, Inc.: Voyager's Tau-Targeted Gene Therapy VY1706 and Anti-Tau Antibody VY7523 for Alzheimer's Disease to Be Featured in Poster Presentations at CTAD 2026 |
Das Unternehmen OS THERAPIES INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 1,300 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OS THERAPIES INC finden Sie auf Wallstreet Online.